New pill aims to shrink spleen and ease symptoms in hard-to-treat bone marrow cancer
NCT ID NCT07379125
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests an oral drug called PMD-026 in 18 adults with myelofibrosis, a type of bone marrow cancer. Participants must have already tried a JAK inhibitor without success. The main goals are to check safety, find the best dose, and see if the drug can shrink the spleen and improve symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug free myelofibrosis patients from frequent blood transfusions?
- Heart safety check for new myelofibrosis drug in healthy volunteers
- Targeted drug aims to stop blood cancer return after transplant
- Could a JAK inhibitor improve stem cell transplant success in myelofibrosis?
- New transplant recipe aims to tame Graft-Versus-Host disease
- New drug candidate targets Hard-to-Treat blood cancers